Industry Satellite Symposia

The 2026 Multidisciplinary Head and Neck Cancers Symposium Education Team has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposia (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2026 Multidisciplinary Head and Neck Cancers Symposium program.

Thursday, February 19

Sinatra Ballroom 9-11
12:30 p.m. - 1:30 p.m.: Symposium
New Immunotherapy Frontiers in HNSCC: Multidisciplinary Perspectives on Advancing Care in Challenging Patient Populations

Learning Objectives 

Upon completion of this activity, learners will:

• Cite updated evidence and practice guidelines supporting emerging immune-based therapeutics for the management of HNSCC
• Develop multidisciplinary care plans that integrate novel immunotherapy options into the personalized treatment of advanced HNSCC
• Utilize team-based strategies to address the practical aspects of immune-based treatment for HNSCC, including care planning, delivery of therapy, and management of AEs

Faculty: 

1. Aarti Bhatia, MD, MPH
2. Barbara Burtness, MD
3. Ranee Mehra, MD

Credit Designation Statement
PVI, PeerView Institute for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by independent educational grants from Johnson & Johnson and Merus.

Sinatra Ballroom 12-14
5:30 p.m. - 6:30 p.m.: Symposium
Multidisciplinary Momentum in Head and Neck Cancers: Elevating Care Across SCCHN and NPC

Learning Objectives 

Upon completion of this activity, learners will:

• Describe the key advances in systemic therapy for H&N cancers
• Apply evidence-based diagnostic and staging strategies for the accurate classification of H&N cancer
• Customize treatment approaches for patients with H&N cancer
• Proactively identify and manage treatment-related toxicities to preserve function and improve quality of life
• Explain the importance of multidisciplinary care in H&N cancer and how best to apply it for optimal outcomes

Target Audience: The target audience is oncologists (including radiation oncologists), pathologists (including head and neck surgeons), radiologists, nurse practitioners (NPs), physician assistants (PAs), and other members of the multidisciplinary oncology care team.

Credit Designation Statement
Medscape Live Meeting Services, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an independent educational grant from Coherus Oncology.

Sinatra Ballroom 9-11
5:30 p.m. - 7:00 p.m.: Symposium
Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting

Learning Objectives 

Upon completion of this activity, learners will:

• Incorporate guideline recommendations for post-CRT surveillance to ensure timely intervention for patients with LA-HNSCC
• Apply risk-stratified strategies to determine appropriate post-CRT management for patients with LA-NSCC
• Implement coordinated multidisciplinary care plans to mitigate and manage toxicities related to CRT in patients with HNSCC
• Identify potentially eligible patients for ongoing clinical trials evaluating novel post-CRT treatment approaches

Target Audience: This educational activity is directed toward medical oncologists, radiation oncologists, head & neck surgery/ENT, speech-language pathologists, NPs/PAs, nurses, pharmacists, and other HCPs involved in the treatment and management of LA-HNSCC.

Program Agenda

• Welcome and Introductions
• Setting the Stage: Current Standards for Post-CRT Care in LA-HNSCC
• Case 1: HPV-Positive LA-HNSCC After CRT
• Case 2: HPV-Negative / Smoking-Associated LA-HNSCC After CRT
• Optimizing Multidisciplinary Care: Surveillance & Toxicity Management Pathways
• Investigational Horizon: Emerging Consolidation Strategies
• Post session Assessment, Questions and Answers, and Conclusions

Credit Designation Statement
Physicians' Education Resource, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an independent educational grant from AstraZeneca.

Friday, February 20

Sinatra Ballroom 9-11
5:30 p.m. - 6:30 p.m.: Symposium
Beyond the Virus: New Strategies to Improve Outcomes of Non-HPV-Associated Recurrent/Metastatic Head and Neck Cancer

Register or learn more.

Learning Objectives

Upon completion of this activity, learners will be able to:

• Explain the implications of human papillomavirus (HPV) status in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) for patient outcomes and quality of life
• Interpret clinical trial data stratified by HPV status to identify limitations of current standard-of-care therapies for non-HPV-associated recurrent/metastatic HNSCC
• Explain how tumor microenvironment factors influence treatment resistance and differential outcomes in non-HPV-associated vs HPV-positive oropharyngeal cancer (OPC)
• Evaluate investigational therapies for non-HPV-associated recurrent/metastatic HNSCC and assess their potential to address unmet clinical needs

Target Audience: Oncologists (including radiation oncologists) and head and neck surgeons globally.

Program Agenda

• Welcome, Faculty Introductions, Overview of Agenda
• Two Diseases, One Name: Why Non-HPV-Associated R/M Head and Neck Cancer Demands Its Own Strategy
• The Data Divide: Uncovering the Divergence in Treatment Outcomes Based on Primary Tumor Site and HPV Status
• How Tumors Build Barriers: Implications of the Microenvironment in Treatment Resistance of Non-HPV-Associated R/M Head and Neck Cancer
• From MOA to Medicine: Translating Knowledge of Therapeutic Innovation in Non-HPV-Associated R/M Head and Neck Cancer?
• Final Remarks, Conclusions, Closing

Faculty: 

1. Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
2. Renata Ferrarotto, MD

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Siyemi Europe and PeerVoice. Siyemi Europe is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
Siyemi Europe designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS.

This activity is supported by an independent educational grant from Bicara Therapeutics.